Table 2.
Comparative synthesis of regenerative medicine clinical studies concentrating on PRP in the management of musculoskeletal pain
| Study ID | Type of pain | Total cohort, n | Age, years | Male, n | Intervention details | Control details | Route of administration | Follow up duration |
|---|---|---|---|---|---|---|---|---|
| Wu (2017) [1] | Lumbar facet joint syndrome | 23 vs 23 | 52.91 ± 7.60 vs 52.78 ± 7.25 | 10 vs 9 | 0.5 mL of autologous PRP for every targeted joint | 0.5% lidocaine and 5 mg/mL betamethasone | Intra-articular | 6 months |
| Tuakli-Wosornu et al. [2•] | Chronic lumbar discogenic pain | 29 vs 18 | 41.40 ± 8.08 vs 43.80 ± 8.91 | 14 vs 2 | 3 – 4 mL of PRP | Contrast agent | Intradiscal | 12 months |
| Singla et al. [3•] | Sacroiliac joint pain | 20 vs 20 | 35.20 ± 12.86 vs 37.00 ± 10.89 | 16 vs 16 | 3 mL of PRP with 0.5 mL of calcium chloride | 1.5 g of methylprednisolone and 1.5 mL of 2% lidocaine with 0.5 mL 0.9% sterile saline | Sacroiliac joint | 3 months |
| Xu et al. [4] | Lumbar disc herniation | 61 vs 63 | 56.0 (44.5–60.0) vs 56.0 (50.0–59.0) | 28 vs 37 | 3 mL of PRP | 2 ml betamethasone + 0.5 ml 0.9% sterile saline + 0.5 ml 2% lidocaine | Transforaminal | 12 months |
| Won et al. [5•] | Chronic non-specific low back pain | 14 vs 16 | 51.0 ± 18.1 vs 50.5 ± 17.0 | 6 vs 6 | 5 – 6 mL of PRP, intradiscal | 6 mL 0.5% lidocaine | Ligament and muscular | 6 months |
| Ruiz-Lopez and Tsai [6] | Chronic degenerative spinal disease | 25 vs 25 | 68 ± 13.06 vs 61 ± 12.60 | 11 vs 10 | 16.5 mL of PRP with 3.5 mL 0.9% sterile saline | 60 mg of triamcinolone acetonide and 3.5 0.9% sterile saline | Epidural | 6 months |
| Akeda (2023) [16•] | Discogenic low back pain | 44 vs 45 | 40.3 ± 10.4 vs 39.1 ± 11.5 | 16 vs 19 | 1 mL of PRP | 1 mL 0.9% sterile saline and 0.2 g Kefzol | Intradiscal | 12 months |
| Zielinski et al. [9•] | Lumbar discogenic pain | 18 vs 8 | n/r | n/r | 2 mL of PRP | 3 mL 0.9% sterile saline | Intradiscal | 8 weeks |
| Mohi Eldin et al. [10] | Discogenic low back pain | 44 vs 88 |
< 40 years: 63 ≥ 40 years: 69 |
n/r | 3 mL of PRP | 3 mL of PRF | Intradiscal | 6 months |
| Akeda (2022) [7•] | Discogenic low back pain | 9 vs 7 | 35.1 ± 8.7 vs 27.9 ± 5.2 | 6 vs 5 | 2 mL of PRP | 2 mg betamethasone and 2 mL 0.9% sterile saline | Intradiscal | 12 months |
Data in “vs” was displayed as intervention vs control